These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8301680)

  • 21. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation.
    Lee KH; Lee JH; Kim S; Lee JS; Kim SH; Kim WK
    Bone Marrow Transplant; 2000 Jul; 26(2):147-52. PubMed ID: 10918424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late ocular complications after bone marrow transplantation.
    Tichelli A
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S79-82. PubMed ID: 8177722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular graft-versus-host disease.
    Hessen M; Akpek EK
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):540-7. PubMed ID: 22892710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ocular manifestations in bone marrow transplantation--case report].
    Karwacka E; Ołdakowska-Jedynak U; Paczek L; Kecik D; Brydak-Godowska J
    Klin Oczna; 2005; 107(7-9):502-5. PubMed ID: 16417007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
    Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
    Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
    Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
    Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Digestive manifestations of graft-versus-host disease (GVHD) in bone marrow transplantation, organ transplantation and transfusion].
    Li V; Molina L; Michallet M; Hostein J
    Gastroenterol Clin Biol; 1992; 16(1):29-36. PubMed ID: 1537479
    [No Abstract]   [Full Text] [Related]  

  • 40. [Ophthalmologic complications of bone marrow transplant].
    Castier P; Jouet JP; Janin-Mercier A; Bochu F; Mancel E
    Bull Soc Ophtalmol Fr; 1989 Feb; 89(2):291-4. PubMed ID: 2805205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.